Asperger syndrome medical therapy: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| (5 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Asperger syndrome}} | {{Asperger syndrome}} | ||
{{CMG}} | {{CMG}} {{AE}} {{SHA}} | ||
==Medical | == Overview == | ||
Medical treatments used in Asperger Syndrome include: [[Stimulant|stimulants]], a-2 [[Adrenergic agonist|adrenergic agonists]], [[atypical antipsychotics]], [[antidepressants]] and [[Anticonvulsant|anticonvulsants]].<ref name="pmid25655905" /> Many studies believe that medications alone can not improve Asperger Syndrome's (AS) symptoms and other complementary interventions (social and behavioral) are required.<ref name="pmid25655905" /> | |||
== Medical Therapy == | |||
* | |||
* | |||
* | |||
* | |||
*Many studies believe that medications alone can not improve Asperger Syndrome's (AS) symptoms and other complementary interventions (social and behavioral) are required.<ref name="pmid25655905" /> | |||
*Medications used in Asperger Syndrome (AS) include:<ref name="pmid25655905">{{cite journal| author=Tarazi FI, Sahli ZT, Pleskow J, Mousa SA| title=Asperger's syndrome: diagnosis, comorbidity and therapy. | journal=Expert Rev Neurother | year= 2015 | volume= 15 | issue= 3 | pages= 281-93 | pmid=25655905 | doi=10.1586/14737175.2015.1009898 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25655905 }} </ref> | |||
**[[Stimulant|Stimulants]] such as [[methylphenidate]] and [[Amphetamine|amphetamines]] (for comorbidity between AS and [[Attention-deficit hyperactivity disorder|attention deficit hyperactivity disorder (ADHD)]]) | |||
** a-2 [[Adrenergic agonist|adrenergic agonists]] such as [[clonidine]] and [[guanfacine]] (treatment of aggression, [[anxiety]] and [[Tourette syndrome|Tourette syndrome (TS)]] which are associated with AS) | |||
**[[Atypical antipsychotics]] such as [[aripiprazole]], [[olanzapine]], [[ziprasidone]] (treatment of aggression, [[Hallucination|hallucinations]], [[hyperactivity]], [[irritability]], anxiety, [[depression]] in AS patients)<ref name="pmid19622537">{{cite journal| author=Crystal S, Olfson M, Huang C, Pincus H, Gerhard T| title=Broadened use of atypical antipsychotics: safety, effectiveness, and policy challenges. | journal=Health Aff (Millwood) | year= 2009 | volume= 28 | issue= 5 | pages= w770-81 | pmid=19622537 | doi=10.1377/hlthaff.28.5.w770 | pmc=2896705 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19622537 }} </ref> | |||
**[[Antidepressants]]<nowiki/>such as [[Selective serotonin reuptake inhibitor|selective serotonin reuptake inhibitors (SSRIs)]] (treatment of depressive disorders and [[Obsessive-compulsive disorder|obsessive compulsive disorder (OCD)]] associated with AS) | |||
**[[Anticonvulsant|Anticonvulsants]](for aggression, [[Mood disorder|mood disorders]], irritability, repetitive behaviors in AS)<ref name="pmid16316486">{{cite journal| author=Hollander E, Soorya L, Wasserman S, Esposito K, Chaplin W, Anagnostou E| title=Divalproex sodium vs. placebo in the treatment of repetitive behaviours in autism spectrum disorder. | journal=Int J Neuropsychopharmacol | year= 2006 | volume= 9 | issue= 2 | pages= 209-13 | pmid=16316486 | doi=10.1017/S1461145705005791 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16316486 }} </ref> <br /> | |||
==References== | ==References== | ||
Latest revision as of 14:27, 22 June 2020
|
Asperger Syndrome Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Asperger syndrome medical therapy On the Web |
|
American Roentgen Ray Society Images of Asperger syndrome medical therapy |
|
Risk calculators and risk factors for Asperger syndrome medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Shakiba Hassanzadeh, MD[2]
Overview
Medical treatments used in Asperger Syndrome include: stimulants, a-2 adrenergic agonists, atypical antipsychotics, antidepressants and anticonvulsants.[1] Many studies believe that medications alone can not improve Asperger Syndrome's (AS) symptoms and other complementary interventions (social and behavioral) are required.[1]
Medical Therapy
- Many studies believe that medications alone can not improve Asperger Syndrome's (AS) symptoms and other complementary interventions (social and behavioral) are required.[1]
- Medications used in Asperger Syndrome (AS) include:[1]
- Stimulants such as methylphenidate and amphetamines (for comorbidity between AS and attention deficit hyperactivity disorder (ADHD))
- a-2 adrenergic agonists such as clonidine and guanfacine (treatment of aggression, anxiety and Tourette syndrome (TS) which are associated with AS)
- Atypical antipsychotics such as aripiprazole, olanzapine, ziprasidone (treatment of aggression, hallucinations, hyperactivity, irritability, anxiety, depression in AS patients)[2]
- Antidepressantssuch as selective serotonin reuptake inhibitors (SSRIs) (treatment of depressive disorders and obsessive compulsive disorder (OCD) associated with AS)
- Anticonvulsants(for aggression, mood disorders, irritability, repetitive behaviors in AS)[3]
References
- ↑ 1.0 1.1 1.2 1.3 Tarazi FI, Sahli ZT, Pleskow J, Mousa SA (2015). "Asperger's syndrome: diagnosis, comorbidity and therapy". Expert Rev Neurother. 15 (3): 281–93. doi:10.1586/14737175.2015.1009898. PMID 25655905.
- ↑ Crystal S, Olfson M, Huang C, Pincus H, Gerhard T (2009). "Broadened use of atypical antipsychotics: safety, effectiveness, and policy challenges". Health Aff (Millwood). 28 (5): w770–81. doi:10.1377/hlthaff.28.5.w770. PMC 2896705. PMID 19622537.
- ↑ Hollander E, Soorya L, Wasserman S, Esposito K, Chaplin W, Anagnostou E (2006). "Divalproex sodium vs. placebo in the treatment of repetitive behaviours in autism spectrum disorder". Int J Neuropsychopharmacol. 9 (2): 209–13. doi:10.1017/S1461145705005791. PMID 16316486.